期刊文献+

剔除自体活化CD4 T淋巴细胞改善骨髓增生异常综合征祖细胞体外培养集落形成

Depleting autologous activated CD4 T lymphocytes improves in vitro generation of colony-forming units in progenitor culture in myelodysplastic syndrome
下载PDF
导出
摘要 目的探讨自体活化CD4 T(CD4+/CCR5+T)淋巴细胞对骨髓增生异常综合征(MDS)祖细胞体外培养细胞集落形成情况的影响。方法用免疫磁珠体外剔除16例低危MDS患者和5例正常人骨髓单个核细胞(BMNC)中CD4+/CCR5+T淋巴细胞,剔除CD4+/CCR5+T及加回CD4+/CCR5+T(4倍)的BMNC分别接种于甲基纤维素培养基中培养,比较培养后细胞集落生长情况,以及培养前后髓系细胞抗原和克隆细胞比例的变化。结果①MDS组剔除CD4+/CCR5+T较加回CD4+/CCR5+T(4倍)的BMNC培养后,细胞集落显著增加(P<0.05),加回CD4+/CCR5+T(4倍)的BMNC培养后无细胞集落形成。而正常对照组剔除CD4+/CCR5+T和加回CD4+/CCR5+T(4倍)的BMNC培养后,细胞集落计数无统计学差异(P>0.05)。②MDS组剔除CD4+/CCR5+T的BMNC培养后,红系集落计数与Th1(CD4+/IFN-γ+)细胞数量呈正相关(r=0.55,P<0.05)。③细胞培养前后,MDS组CD34阳性细胞比例无明显下降[(1.8±2.4)%vs(1.4±1.6)%](P>0.05),CD33和CD13阳性细胞比例均有显著下降[(20.3±5.8)%vs(12.1±3.7)%和(21.1±6.4)%vs(17.1±5.4)%](P<0.05);而正常对照组CD34、CD33及CD13阳性细胞比例在培养前后均无明显变化(P>0.05)。④FISH分析5例核型异常MDS患者培养前后克隆细胞比例变化,+8及20q-克隆细胞比例增加,而-7克隆细胞比例无明显变化。结论选择性剔除骨髓CD4+/CCR5+T淋巴细胞,可以增加某些类型MDS骨髓祖细胞体外培养细胞集落形成,并改善MDS骨髓早期髓系细胞堆积现象,促进分化。增加的集落细胞以异常克隆细胞或残存正常细胞为主尚不能定论。 Objective To investigate the effects of autologous activated CD4 T(CD4^+/CCR5^+ T)lymphocytes on in vitro generation of colony-forming units (CFU) in progenitor culture in myelodysplastic syndrome (MDS). Methods Bone marrow mononuclear cells (BMNC) from 16 patients with low-grade MDS and 5 normal donors were depleted of CD4 ^+/ CCR5^+ T lymphocytes using magnetic sorting. CD4^+/CCR5^+ T lymphocyte-depleted and lymphocyte-plused (4-fold) BMNC were seeded onto methylcellulose medium. The generation of CFU after culture, the medullary cell antigen and rate of clonal ceils before and after culture were analyzed and compared. Results Cultures initiated with CD4^+/CCR5 ^+ T lymphocyte-depleted BMNC from patients with MDS exhibited significantly increased generation of CFU compared with the corresponding CD4^+/CCR5^+ T (4-fold) lymphocyte-plused cultures (P 〈 0. 05). However, there was no significant difference in the generation of CFU between CD4^+/CCR5^+ T lymphocyte-depleted and CD4^+/CCR5^+ T (4-fold) lymphocyte-plused BMNC cultures from normal donors (P 〉 0.05). The number of Thl ( CD4 ^+/IFN-γ^+ ) cells in patients with MDS was positively related to that of colony-forming unit erythroid (CFU-E) after culture with CD4^+/CCR5^+ T lymphocyte-depleted BMNC from patients with MDS(r = 0.55, P 〈 0.05). There was no significant decrease in the rate of CD34 positive cells before culture and after culture in patients with MDS [ ( 1.8 ± 2.4) % vs ( 1.4 ± 1.6) % ] (P 〉 0.05 ), while there was significant decrease in the rates of CD33 and CD13 positive cells [ (20.3 ± 5.8) % vs ( 12.1 ± 3.7) % and (21.1 ± 6.4) % vs ( 17.1 ± 5.4) % ] ( P 〈 0.05 ). And there was no significant difference in the rates of CD34, CD33 and CD13 positive cells before culture and after culture in normal donors (P 〉 0.05). FISH analysis was performed to compare the elonal cell proportions in 5 cases with abnormal chromosome before culture and after culture, and it was found that +8 and 20q^- clone cells were increased, while there was no significant change in - 7 clone cells. Conclusion In certain subtypes of MDS, selected depletion of CD4^+/CCR5^+ T lymphocytes can increase in vitro generation of CFU in progenitor culture, improve prophase medullary cell accumulation in MDS cases and promote differentiation of MDS medullary system. However, whether the increased CFU are consisted of residual normal hemopoiesis or abnomal hemopoiesis are undetermined.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2009年第2期139-144,共6页 Journal of Shanghai Jiao tong University:Medical Science
基金 上海市科委引导项目(064119635)~~
关键词 骨髓增生异常综合征 T淋巴细胞 免疫抑制 细胞培养 myelodysplastic syndrome T lymphocyte immunosuppression cell culture
  • 相关文献

参考文献18

  • 1Kochenderfer JN, Kobayashi S, Wieder ED,et al. Loss of T-lympho cyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression [ J ] .Blood, 2002, 100 ( 18 ) : 3639 - 3645.
  • 2Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles[ J]. Br J Haematol, 1998,102 (5) : 1314 - 1322.
  • 3Baumann I, Scheid C, Koref MS, et al. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome[ J]. Exp Hematol,2002,30(12) : 1405 - 1411.
  • 4Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology[ J] .9 Semin Hematol,2000,37( 1 ) : 15 -29.
  • 5Giannakoulas NC, Karakantza M, Theodorou GL, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients [ J]. Br J Haematol,2004,124( 1 ) :97 - 105.
  • 6Wu LY, Li X, Chang CK, et al. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome[ J]. Int J Lab Hematol,2008,30(5) :390 -399.
  • 7Greenberg P, Cox C, LeBeau MM,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [ J ]. Blood, 1997,89(6) :2079 -2088.
  • 8Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hemato- poietic cells but not in cells with other cytogenetic abnormalities [ J ].Blood,2002,100 ( 13 ) :4427 - 4432.
  • 9Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines[ J]. Int J Hematol, 1996,63 (4) :265 -278.
  • 10吴凌云,李晓,常春康,应韶旭,浦权.骨髓增生异常综合征患者T细胞异常极化导致的负性造血调控[J].中华血液学杂志,2007,28(8):549-554. 被引量:4

二级参考文献15

  • 1王秀丽,邵宗鸿,姚程,何广胜,刘鸿,施均,白洁,曹燕然,涂梅峰,王化泉,邢莉民,孙娟,贾海蓉,杨崇礼.骨髓增生异常综合征患者骨髓T辅助细胞亚群的研究[J].中华血液学杂志,2005,26(12):743-745. 被引量:17
  • 2Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: muhicenter pilot studies in Japan. Leuk Res, 2003, 27: 783-788.
  • 3Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase Ⅱ study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with lowrisk myelodysplastic syndromes. Leukemia, 2004, 18: 460-465.
  • 4Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic diseases of the hematopietic and lymphoid tissues: report of the Clinical Advisory Committee meeting Article House, Virginia, November 1997. J Clin Oncol, 1999, 17: 3835-3849.
  • 5Greenberg P, Cox C, Le Beau MM, et al. International scoring systerm (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood, 1997, 89: 2079-2088.
  • 6Invernizzi R, Pecci A, Bellotti L, et al. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma, 2001, 42: 481-489.
  • 7Yazji S, Gile FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG) based therapy in patients with myelodysplastic syndromes. Leukemia, 2003, 17 : 2101-2106.
  • 8Romagnami S. Human Th1 and Th2 subsets: doubt no more. Immunol Today, 1991, 12: 256-257.
  • 9Tsuda H, Yamasaki H. Type I and type Ⅱ T-cell profiles in aplastic anemia and refractory anemia. Am J Hematol, 2000, 64: 271-274.
  • 10Li X, Bryant CE, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol, 2004, 80: 140-145.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部